Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Article in English | MEDLINE | ID: mdl-36231241

ABSTRACT

Against the backdrop of the COVID-19 pandemic, it is necessary to identify these risks and determine whether the current level of management is appropriate to respond to the risk of biological hazards depending on the occupation. In this study, the incidence and fatality rates of occupational diseases were calculated using industrial accident statistics of South Korea, and trends by year using joinpoint regression and relative risk by industry using k-means clustering were evaluated for infectious diseases. We found that infectious diseases had the third highest incidence and fourth highest fatalities among all occupational diseases. In the incidence rate, joinpoints appeared in 2009 and 2018, and the annual percent change changed to 7.79, -16.63, and 82.11. The fatality rate showed a consistent increase with an annual percent change of 4.37, but it was not significant. Industries were classified into five groups according to risk, and the legal control measures of certain industries were not sufficient. Follow-up studies are needed to rectify the structural limitations of industrial accident statistics.


Subject(s)
COVID-19 , Communicable Diseases , Occupational Diseases , Accidents, Occupational , COVID-19/epidemiology , Cluster Analysis , Communicable Diseases/epidemiology , Humans , Occupational Diseases/epidemiology , Pandemics , Republic of Korea/epidemiology
2.
Iran J Allergy Asthma Immunol ; 15(2): 138-44, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27090367

ABSTRACT

The prevalence of atopic dermatitis (AD) and obesity have been increasing considerably in Korean school-children. AD is a chronic pruritic recurrent inflammatory skin disorder. Leptin is secreted by adipocytes which has been suggested to be immunologically active; however, their role in AD has not yet been well understood. A total of 227 subjects out of 2,109 elementary school children were defined as having AD based on the ISAAC questionnaire survey. Ninety subjects with AD, aged between 6 and 12 years, completed scoring of severity of AD (SCORAD), skin prick testing, blood tests for total IgE, eosinophil counts, eosinophil cationic protein (ECP) and lipid profiles. Serum leptin levels were also measured. A subject with atopic AD was defined as an AD patient showing at least 1 positive reaction to allergens in skin prick testing. There were no significant differences in age, body mass index, percentage of breast milk feeding, mode of delivery, prevalence of atopy, and lipid profiles between atopic AD and non-atopic AD subjects. The serum leptin levels (log mean±SD) were significantly higher in non-atopic AD group than in the atopic AD group (0.86±0.57 ng/mL vs 0.53±0.72 ng/mL, p=0.045). Subjects with mild-to-moderate AD showed significantly higher serum leptin levels than those with severe AD (0.77±0.67 ng/mL vs 0.33±0.69 ng/mL, p=0.028). There was a marginal inverse correlation between the SCORAD index and the serum leptin concentration in total AD subjects (r=-0.216, p=0.053). The serum leptin levels were significantly higher in non-atopic AD subjects or mild-to-moderate AD subjects. Leptin did not seem to be associated with IgE-mediated inflammation in AD. Obesity-associated high leptin differed between non-atopic AD and atopic AD subjects.


Subject(s)
Dermatitis, Atopic/blood , Leptin/blood , Child , Cross-Sectional Studies , Dermatitis, Atopic/epidemiology , Dermatitis, Atopic/immunology , Eosinophil Cationic Protein/blood , Eosinophil Cationic Protein/immunology , Female , Humans , Immunoglobulin E/blood , Immunoglobulin E/immunology , Leptin/immunology , Leukocyte Count , Lipids/biosynthesis , Lipids/immunology , Male , Obesity/blood , Obesity/immunology , Republic of Korea
3.
Iran J Allergy Asthma Immunol ; 14(1): 28-36, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25530136

ABSTRACT

Asthma and atopic dermatitis are common allergic diseases, and their prevalence has increased in urban children. Recently, it is becoming understood that forest environment has favorable health effects in patients with chronic diseases. To investigate favorable clinical and immunologic effects of forest, we examined changes in clinical symptoms, indirect airway inflammatory marker, and serum chemokines before and after a short-term forest trip. The forest trips were performed with 21 children with asthma and 27 children with atopic dermatitis. All participating children were living in air polluted urban inner-city. We measured spirometry and fractional exhaled nitric oxide (FeNO) in children with asthma and measured scoring atopic dermatitis (SCORAD) index and Thymus and Activation-Regulated Chemokine (TARC)/CCL17 and Macrophage-Derived Chemokine (MDC)/CCL22 levels in children with atopic dermatitis before and after the forest trip. Indoor air pollutants such as indoor mold, particulate matter 10 (PM10) and total volatile organic compounds (TVOCs) of each child's home and the accommodations within forest were measured. A significant increase in forced vital capacity (FVC) and a significant decrease in FeNO were observed after the forest trip in children with asthma. SCORAD indices and MDC/CCL22 levels were significantly decreased after the forest trip in children with atopic dermatitis. Airborne mold and PM10 levels in indoor were significantly lower in the forest accommodations than those of children's homes; however, TVOC levels were not different between the two measured sites. Short-term exposure to forest environment may have clinical and immunological effects in children with allergic diseases who were living in the urban community.


Subject(s)
Asthma/immunology , Dermatitis, Atopic/immunology , Forests , Air Pollutants/adverse effects , Air Pollutants/analysis , Asthma/etiology , Chemokine CCL17/blood , Chemokine CCL22/blood , Child , Dermatitis, Atopic/etiology , Female , Humans , Male , Respiratory Function Tests , Urban Population
4.
Biosci Biotechnol Biochem ; 78(6): 1082-5, 2014.
Article in English | MEDLINE | ID: mdl-25036139

ABSTRACT

To investigate the combinatorial effects using Salmonella and γ-radiation, the Salmonella typhimurium infection in combination with γ-radiation was investigated on melanoma. We showed that ROS expression and H2AX phosphorylation increased during stress by γ-radiation irrespective of Salmonella infection, inducing apoptosis by caspase-3 and bcl2 in tumor cells. In addition, tumor growth was suppressed by this combinatory therapy suggesting candidates for radiation therapy against melanoma.


Subject(s)
Apoptosis/radiation effects , Gamma Rays/therapeutic use , Histones/metabolism , Melanoma/pathology , Salmonella typhimurium/physiology , Animals , Cell Line, Tumor , Cell Proliferation/radiation effects , Mice , Phosphorylation/radiation effects , Reactive Oxygen Species/metabolism
5.
DNA Cell Biol ; 31(3): 290-7, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21823987

ABSTRACT

Atopic dermatitis (AD) is an inflammatory, chronically relapsing, puritic skin disorder. These syndromes result from multifactorial inheritance, with interaction between genetic and environmental factors. In particular, the macrophage-derived chemokine CCL22 is directly implicated in skin inflammatory reactions and its levels are significantly elevated in serum and correlated with disease severity in AD. We tested the suppression of the CCL22 gene by microRNA (miRNA) and observed the effects in mice with inflammation similar to AD. We used Salmonella as a vector to deliver miRNA. The recombinant strain of Salmonella typhimurium expressing CCL22 miRNA (ST-miRCCL22) was prepared for in vivo knockdown of CCL22. ST-miRCCL22 was orally inoculated into mice and the CCL22 gene suppressed with CCL22 miRNA in the activated lymphocytes. IgE and interleukin-4 were inhibited and interferon-γ was induced after treatments with ST-miRCCL22 and CCL22 was suppressed. Further, Th17 cells were suppressed in the atopic mice treated with ST-miRCCL22. These results suggested that suppression of the CCL22 gene using Salmonella induced anti-inflammatory effects.


Subject(s)
Chemokine CCL22/genetics , Dermatitis, Atopic/genetics , Dermatitis, Atopic/immunology , MicroRNAs/genetics , Salmonella typhimurium/genetics , Animals , Cell Line , Dermatitis, Atopic/pathology , Female , Genetic Vectors , Mice , Mice, Inbred ICR
6.
J Gen Appl Microbiol ; 57(2): 115-22, 2011.
Article in English | MEDLINE | ID: mdl-21606612

ABSTRACT

IL-12 is known to be an essential cytokine which appears to provide protective immunity against intracellular bacteria, such as Salmonella. In this study, we investigated the possibility of developing a vaccine using IL-12 against virulent Salmonella. We used the host defense system activated by cytokine IL-12. The highly virulent Salmonella strain (Salmonella typhimurium UK-1) was transformed with cytokine-expressing plasmids. These live, wild-type pathogens were used as vaccine strains without undergoing any other biological or genetic attenuating processes. The newly developed strains induced partial protection from infections (30-40%). Of note, the interleukin-12-transformed pathogen was safe upon immunization with low doses (10(3) cfu), induced IgG responses, and stimulated protective immune responses against Salmonella typhimurium in mice (80-100%). These results suggest that IL-12 induced attenuation of wild-type Salmonella in the host infection stage and vaccine development using the wild-type strain harboring plasmid-secreting IL-12 may be considered as an alternative process for intracellular bacterial vaccine development without the inconvenience of time-consuming attenuation processes.


Subject(s)
Interleukin-12/immunology , Plasmids , Salmonella Infections/prevention & control , Salmonella Vaccines/genetics , Salmonella Vaccines/immunology , Salmonella typhimurium/genetics , Salmonella typhimurium/immunology , Animals , Interleukin-12/genetics , Mice , Mice, Inbred BALB C , Salmonella Vaccines/administration & dosage , Salmonella Vaccines/adverse effects , Salmonella typhimurium/pathogenicity , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/adverse effects , Vaccines, Attenuated/genetics , Vaccines, Attenuated/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology
7.
Exp Mol Med ; 43(2): 63-70, 2011 Feb 28.
Article in English | MEDLINE | ID: mdl-21187702

ABSTRACT

Th-2-biased immune responses are known to play a key role in the pathogenesis of atopic dermatitis. In particular, the macrophage-derived chemokine CCL22 is directly implicated in Th-2-associated skin inflammatory reactions, and its levels are significantly elevated in serum and are correlated with disease severity in atopic dermatitis. In this study, we tested the development of genetic therapeutic options to treat atopic dermatitis using bacteria expressing miRNA. We constructed a recombinant strain of Salmonella typhimurium expressing CCL22 miRNA (ST-miRCCL22) for the in vivo knockdown of CCL22. The CCL22 gene was downregulated with CCL22 miRNA in activated lymphocytes. In mice with a cutaneous disease similar to atopic dermatitis, interleukin-4 was inhibited and interferon-g was induced after treatments with ST-miRCCL22. Furthermore, CCL22 levels were suppressed in the atopic mice treated with ST-miRCCL22. These results suggest that ST-miRCCL22 may be an effective genetic agent for treating atopic dermatitis.


Subject(s)
Chemokine CCL22 , MicroRNAs , Organisms, Genetically Modified , Salmonella typhimurium , Skin/drug effects , Animals , Cell Line , Chemokine CCL22/genetics , Cytokines/blood , Dermatitis, Atopic/pathology , Disease Models, Animal , Female , Gene Expression Regulation/drug effects , Gene Silencing , Immunoglobulin E/blood , Mice , MicroRNAs/genetics , MicroRNAs/pharmacology , Organisms, Genetically Modified/genetics , Salmonella typhimurium/genetics , Salmonella typhimurium/metabolism , Skin/pathology
8.
Appl Microbiol Biotechnol ; 89(6): 1807-19, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21113588

ABSTRACT

Although the use of TNF-α in the treatment of cancer is restricted due to its non-specific cytotoxicity and narrow range of applications to different cancers in clinical trials, we investigated a safe anti-cancer drug by the use of engineered bacterial capsule harboring TNF-α. The engineered bacterial capsule was designed to target cancer cells, promote a tumor-suppressive environment, and increase the efficacy of existing cancer treatments, including chemotherapy, radiotherapy, and cell therapy. The engineered bacterial capsule was constructed with Salmonella capsulizing TNF-α protein, which was produced and capsulized by Salmonella to reduce side effects of the protein. This bacterial capsule induced a tumor-suppressive environment through the activation of natural killer cells. Engineered bacterial capsule invaded tumor cells, released TNF-α, and induced apoptosis of tumor cells without apparent side effects. In a murine melanoma model, the bacterial capsule of TNF-α significantly inhibited tumor growth by 80-100% and prolonged the survival of the mice. When tested in combination with chemotherapy (cisplatin), antibiotics, and vaccine, recombinant microbial treatment increased the anti-tumor effects of existing therapies. The anti-tumor effects of the bacterial capsule of TNF-α were also observed in cervical cancer, melanoma, breast cancer, colon cancer, and renal carcinoma. These results suggest that the bacterial capsule of TNF-α is a promising strategy for TNF-α treatment.


Subject(s)
Antineoplastic Agents/metabolism , Bacterial Capsules/metabolism , Melanoma/therapy , Salmonella typhimurium/metabolism , Tumor Necrosis Factor-alpha/metabolism , Animals , Bacterial Capsules/genetics , Disease Models, Animal , Killer Cells, Natural/immunology , Mice , Salmonella typhimurium/genetics , Survival Analysis , Tumor Necrosis Factor-alpha/genetics
9.
J Bacteriol ; 189(6): 2417-25, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17209022

ABSTRACT

In Salmonella enterica serovar Typhimurium, the membrane-localized CadC is a transcriptional activator of the cadBA operon, which contributes to the acid tolerance response. Unlike in Escherichia coli, in which transcription of cadC is constitutive, in S. enterica serovar Typhimurium cadC expression is induced by low pH and lysine. Inactivation of cadC suppresses the acid-sensitive phenotype of a cadA mutation, suggesting the existence of other CadC-dependent genes in addition to the cadBA operon. Using a proteomic approach, we identified 8 of the putative CadC-induced proteins and 15 of the putative CadC-repressed proteins. The former include porin proteins OmpC and OmpF. The latter include proteins involved in glycolysis, energy production, and stress tolerance. To better understand the altered levels of OmpC and OmpF, we compared expression of ompR in S. enterica serovar Typhimurium wild-type and cadC mutant strains and determined that CadC exerted a negative influence on ompR transcription. Taken together, our findings strongly suggest that CadC may be a global regulator involved in the OmpR regulatory system during acid adaptation.


Subject(s)
Bacterial Proteins/metabolism , Gene Expression Regulation, Bacterial , Salmonella typhimurium/physiology , Bacterial Proteins/genetics , Culture Media , Humans , Hydrogen-Ion Concentration , Lysine/pharmacology , Mutation , Porins/genetics , Porins/metabolism , Protein Biosynthesis , Proteome , Salmonella typhimurium/drug effects , Salmonella typhimurium/genetics , Salmonella typhimurium/metabolism
10.
Biotechnol Lett ; 29(4): 511-6, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17235489

ABSTRACT

An attenuated strain of Salmonella typhimurium has been tested in animals and clinically as an anticancer agent due to its in vivo tumor-targeting and tumoricidal properties. We exploited a genetically-engineered S. typhimurium harboring Flt3 Ligand (Flt3L) expression vectors as a tumoricidal agent to enhance its therapeutic efficacy. Flt3L showed tumoricidal effects when expressed in tumor cells in vitro. When melanoma-bearing mice were treated locally with Salmonella, S. typhimurim with Flt3L expression vectors inhibited tumor growth more than Salmonella controls (50% vs. 0% in tumor regression rates). Moreover, it prolonged survivals of animals without induction of memory antitumor protective responses to a parental tumor re-challenge (50% vs. 0% in survival rates). These results suggest that a genetically engineered S. typhimurium with Flt3L expression vectors has the potential to be applicable as a safer and more effective tumor-targeting and tumoricidal agent.


Subject(s)
DNA, Bacterial/administration & dosage , Melanoma/pathology , Melanoma/therapy , Membrane Proteins/genetics , Plasmids/administration & dosage , Salmonella typhimurium/genetics , Transfection/methods , Animals , Cell Line, Tumor , Genetic Therapy/methods , Genetic Vectors/genetics , Melanoma/genetics , Membrane Proteins/therapeutic use , Mice , Mice, Inbred C57BL
11.
Biosci Biotechnol Biochem ; 67(11): 2344-50, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14646192

ABSTRACT

Telomerase is a ribonucleoprotein complex the function of which is to add telomeric repeats (TTAGGG)(n) to chromosomal ends, and it is known to play an important role in cellular immortalization. Telomerase is highly active in most tumor cells, yet not in normal cells. As such, it may have possible applications in cancer gene therapy. Telomerase consists of two essential components, telomerase RNA template (hTR) and catalytic subunit (hTERT). hTERT is expressed only in cells and tissues positive for telomerase activity, i.e., tumor and fetal cells. We here tested the possibility of the utilization of the hTERT promoter in targeted cancer gene therapy. We cloned the hTERT promoter in the replace of the CMV promoter and sub-cloned HSV-TK gene to be controlled by hTERT gene promoter in adenovirus shuttle plasmid. Then we constructed recombinant adenovirus Ad-hT-TK, and infected them into normal and human gynecological cancer cell lines. Through these experiments, we identified the selective tumor specific cell death by Ad-hT-TK. Furthermore, FACS analysis and TUNEL assay suggests that the reduced viability is mediated through the induction of apoptosis, indicating that this approach may be a useful method for suppressing cancer growth in targeted cancer gene therapy. These results show that Ad-hT-TK could be used for gynecological cancer gene therapy.


Subject(s)
Adenoviridae/genetics , Genetic Therapy/methods , Ovarian Neoplasms/therapy , Telomerase/genetics , Apoptosis , Cell Line , Cell Line, Tumor , Cloning, Molecular , DNA-Binding Proteins , Female , Fibroblasts/enzymology , Genes, Reporter , Humans , Luciferases/analysis , Luciferases/genetics , Plasmids/genetics , Promoter Regions, Genetic , Protein Subunits/genetics , Reverse Transcriptase Polymerase Chain Reaction
12.
DNA Cell Biol ; 21(2): 99-107, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11953009

ABSTRACT

To evaluate the peptidoglycan-associated lipoprotein (PAL) antigen of Legionella pneumophila as a vaccine candidate, mice were immunized intramuscularly with pcDNA3-PAL and intraperitoneally with recombinant PAL (t-rPAL), which were compared for their ability to induce PAL-specific immune responses. The t-rPAL protein induced PAL-specific IgG antibody production significantly more than did pcDNA3-PAL. The IgG2a and IgG1 production was predominant after pcDNA3-PAL and t-rPAL administration, respectively. In particular, pcDNA3-PAL induced much higher PAL-specific cytotoxic T-lymphocyte responses than did t-rPAL. Furthermore, in vivo, CD19+ B-cell populations were dramatically increased by t-rPAL vaccination, suggesting a B-cell immunomodulatory activity of the lipoprotein. The PAL antigen was also conserved among Legionella species, as determined by PCR and immunoblot analyses. These results support a potential use of the t-rPAL protein and in particular DNA vaccines against Legionella infections.


Subject(s)
Antibodies, Bacterial/biosynthesis , Antigens, Bacterial/immunology , Bacterial Outer Membrane Proteins , Bacterial Proteins/immunology , Bacterial Vaccines/immunology , Legionella/immunology , Lipoproteins/immunology , Peptidoglycan/immunology , Proteoglycans , T-Lymphocytes, Cytotoxic/immunology , Vaccines, DNA/immunology , Animals , Antigens, Bacterial/administration & dosage , Antigens, Bacterial/genetics , Bacterial Proteins/genetics , Cytokines/metabolism , Escherichia coli Proteins , Female , Immunity, Cellular , Immunization , Immunization, Secondary , Immunoglobulin G/biosynthesis , Injections, Intramuscular , Injections, Intraperitoneal , Legionella/classification , Legionella pneumophila/immunology , Lipoproteins/genetics , Mice , Mice, Inbred BALB C , Peptidoglycan/genetics , Rabbits , Serotyping , Species Specificity , Specific Pathogen-Free Organisms , Th1 Cells/immunology , Th1 Cells/metabolism , Vaccines, Synthetic/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...